MASH and Liver Fibrosis Therapeutics Clinical Landscape Report 2026: Trials, Readouts and White Space
Turn fragmented clinical intelligence into a decision-ready landscape. This report was assembled with PatSnap MCP Servers for Clinical Trials, Drug & Asset, and Company & Deal Intelligence. Explore the PatSnap MCP Marketplace to bring the same structured evidence into your own AI workflow.
Data snapshot: 16 July 2026. This landscape is a strategic research view, not medical advice. Trial status and timing can change; confirm records before making development or investment decisions.
Executive view
MASH development is splitting into noncirrhotic histology programs, cirrhosis outcomes trials, metabolic weight-loss approaches, RNA therapeutics, and FGF21 analogs—each with different readout clocks and commercial risk.
How this report was built with PatSnap MCP
The workflow first used the Clinical Trials MCP to search the topic and then called clinical_trial_fetch for design details: phase, status, enrollment, sponsor, geography, primary endpoint and expected timing. It separately used clinical_trial_result_fetch to inspect indexed readouts. The Drug & Asset MCP drug_fetch call added target and global development status, while Company & Deal Intelligence organization_fetch added sponsor context. This sequence keeps trial claims traceable and prevents asset-level assumptions from being inferred from a company name alone.
Trial landscape table
| Trial | Asset / mechanism | Phase / status | Sponsor | Geography | Primary endpoint | Readout |
|---|---|---|---|---|---|---|
| NCT07701993 | Efimosfermin alfa | Phase 3; not yet recruiting | GSK | Not listed | Composite liver-related clinical outcome | Primary completion Jul 2033 |
| JPRN-jRCT2041260085 | Efimosfermin alfa NEBULA-2 | Phase 3; planned | GSK KK | 30 markets | ≥1-stage fibrosis improvement without MASH worsening | Timing not listed |
| NCT07631637 | ALN-CIDEB RNAi | Phase 2; not yet recruiting | Regeneron | Not listed | MRI-PDFF liver-fat change at week 26 | Primary completion Feb 2029 |
| NCT07491458 | HU6 | Phase 2; recruiting | Rivus Pharmaceuticals | United States | Safety and MRI-PDFF at week 26 | Primary completion Feb 2027 |
The table is intentionally decision-oriented: endpoint choice, geographic reach and readout timing are displayed beside phase and sponsor. A large Phase 3 program can still have a long evidence gap, while a small Phase 2 study may answer a strategically important biomarker or tolerability question sooner.
What the indexed results say
- Efimosfermin alfa Phase 2 results described gastrointestinal events as the most frequent AEs and generally transient early in treatment.
- Resmetirom post-hoc reporting extends attention beyond histology to patient-reported cognitive function.
- Belapectin illustrates the difficulty and long duration of cirrhosis trials anchored to prevention of clinical complications.
Result records should be interpreted in context. Cross-trial comparisons can be distorted by population, baseline risk, estimand, dose, follow-up and analysis set. The useful signal is not a simplistic ranking; it is how each result changes the next development question.
Build your own living clinical map: connect to PatSnap MCP Servers and combine trial design, result, asset and organization records without manually reconciling multiple databases.
Asset and sponsor context
Drug & Asset records show approved THR-beta agonist resmetirom, Phase 3 FGF21 analog efimosfermin alfa, Phase 2 CIDEB RNAi ALN-CIDEB, and Phase 2 mitochondrial uncoupler HU6. GSK (GSK), Regeneron (REGN), and private Rivus span distinct sponsor profiles.
Where the white space is
- Validated noninvasive endpoints that can bridge reliably to outcomes.
- Cirrhosis studies powered for decompensation rather than short-term fat reduction.
- Combination designs pairing metabolic, anti-inflammatory and antifibrotic mechanisms.
- Evidence in lean MASH and geographically diverse populations.
Strategic implications
For sponsors, the strongest differentiation opportunity is usually not “another asset in the same class.” It is a trial package that resolves a known decision gap: an active comparator, a better-defined responder population, a safer delivery model, a hard outcome, or a credible plan for sequencing. For business-development teams, the same landscape can identify assets whose mechanism is crowded but whose evidence architecture is differentiated. For investors, endpoint maturity and operational feasibility deserve as much attention as nominal phase.
What to monitor next
Track status changes, protocol amendments, primary-completion dates, newly indexed results, and sponsor ownership. Re-run the same MCP queries on a schedule and compare deltas rather than rebuilding the landscape from scratch. Pay special attention when an endpoint moves from a surrogate to a clinical outcome, when a single-country program becomes multinational, or when an emerging sponsor adds a large pharmaceutical collaborator.
Bottom line
MASH and Liver Fibrosis Therapeutics is a fast-moving clinical field with meaningful competition and equally meaningful evidence gaps. A useful landscape must connect design, results, mechanism and sponsor—not list trials in isolation.
Ready to reproduce this analysis? Explore PatSnap MCP Servers and use Clinical Trials, Drug & Asset, and Company & Deal Intelligence as structured building blocks for research, monitoring and SEO-ready clinical reports.
